Key result
Untargeted lipidomics can identify plasma lipids altered by anthracycline-based chemotherapies to serve as nutritional targets for attenuating declines in left ventricular ejection fraction.
Why the study?
Anthracycline-based chemotherapies reduce LVEF and exercise capacity in breast cancer survivors, increasing heart failure risk, and lipidomic profiling may identify nutritional targets to mitigate these declines.
Untargeted lipidomics may identify plasma lipid alterations caused by anthracycline-based chemotherapies, potentially serving as nutritional targets to attenuate declines in LVEF and exercise capacity.
Objectives: Anthracycline-based chemotherapies (anth-bc) reduce left ventricular ejection fraction (LVEF) and exercise capacity placing breast cancer (BC) survivors at an increased risk of heart failure. Application of untargeted lipidomics can identify plasma lipids altered by anth-bc to serve as nutritional targets that attenuate declines in clinical assessments.
No takes yet. Share an insight, caveat, or question.
Bellissimo et al. (2026) studied this question. Untargeted lipidomics can identify plasma lipids altered by anthracycline-based chemotherapies to serve as nutritional targets for attenuating declines in left ventricular ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: